Scientists at the University of York in the UK have discovered that a drug used widely to combat epilepsy has the potential to reduce the growth and spread of breast cancer. Researchers in the Department of Biology at York studied phenytoin, a drug that inhibits epilepsy by targeting sodium channels. These channels, known as VGSCs, exist in the membranes of excitable cells, such as neurons, where they are involved in transmission of electrical impulses. They are also present in breast cancer cells where they are thought to help the spread of tumors. In research published in Molecular Cancer, the York team found that “repurposing” anti-epileptic drugs, such as phenytoin, that effectively block the sodium channels, could provide a novel therapy for cancer. Despite extensive work to define the molecular mechanisms underlying the expression of VGSCs and their pro-invasive role in cancer cells, there is little clinically relevant in vivo data exploring their value as potential therapeutic targets. The researchers found that treatment with phenytoin, at doses equivalent to those used to treat epilepsy significantly reduced tumor growth in a preclinical model. Phenytoin also reduced cancer cell proliferation in vivo and aslso reduced invasion into surrounding mammary tissue. Dr. Will Brackenbury, who led the research, said, “This is the first study to show that phenytoin reduces both the growth and spread of breast cancer tumor cells. This indicates that re-purposing antiepileptic and antiarrhythmic drugs is worthy of further study as a potentially novel anti-cancer therapy.” The research was funded by the Medical Research Council and the University of York. Some of the analysis was carried out by the proteomics team in the University’s Bioscience Technology Facility. The research team also included Michaela Nelson, Ming Yang, Adam A.
Login Or Register To Read Full Story